Vycor Medical, Inc. VYCO
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -193.31% | 152.07% | -835.82% | 108.19% | 339.00% |
| Total Depreciation and Amortization | -4.00% | -2.48% | -4.73% | 1.27% | -4.46% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -99.46% | -48.37% | -98.37% | 219.15% | -- |
| Change in Net Operating Assets | 127.78% | 337.72% | 227.99% | -316.83% | -113.45% |
| Cash from Operations | -110.30% | 469.52% | 202.35% | -789.52% | -45.81% |
| Capital Expenditure | -- | -- | -- | 100.00% | -- |
| Sale of Property, Plant, and Equipment | -62.50% | -- | -100.00% | -100.00% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 110.71% | -- | -900.00% | 100.00% | -- |
| Total Debt Issued | -- | -- | -- | -3.28% | -- |
| Total Debt Repaid | -96.15% | 15.82% | -7.19% | 21.35% | 50.94% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -96.15% | 15.82% | -7.19% | 12.46% | 50.94% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -137.98% | 294.39% | 143.85% | -192.69% | -48.67% |